207 related articles for article (PubMed ID: 25212525)
1. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles.
Kao CH; Wang JY; Chuang KH; Chuang CH; Cheng TC; Hsieh YC; Tseng YL; Chen BM; Roffler SR; Cheng TL
Biomaterials; 2014 Dec; 35(37):9930-9940. PubMed ID: 25212525
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.
Chen IJ; Cheng YA; Ho KW; Lin WW; Cheng KW; Lu YC; Hsieh YC; Huang CC; Chuang CH; Chen FM; Su YC; Roffler SR; Cheng TL
Acta Biomater; 2020 Jul; 111():386-397. PubMed ID: 32417267
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy.
Lin WW; Cheng YA; Li CC; Ho KW; Chen HJ; Chen IU; Huang BC; Liu HJ; Lu YC; Cheng CM; Huang MY; Lai HW; Cheng TL
Sci Rep; 2021 Apr; 11(1):7598. PubMed ID: 33828191
[TBL] [Abstract][Full Text] [Related]
4. Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.
Cheng YA; Chen IJ; Su YC; Cheng KW; Lu YC; Lin WW; Hsieh YC; Kao CH; Chen FM; Roffler SR; Cheng TL
Biomater Sci; 2019 Aug; 7(8):3404-3417. PubMed ID: 31251311
[TBL] [Abstract][Full Text] [Related]
5. Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer.
Cheng YA; Wu TH; Wang YM; Cheng TL; Chen IJ; Lu YC; Chuang KH; Wang CK; Chen CY; Lin RA; Chen HJ; Liao TY; Liu ES; Chen FM
J Nanobiotechnology; 2020 Aug; 18(1):118. PubMed ID: 32854720
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors.
Su CY; Chen M; Chen LC; Ho YS; Ho HO; Lin SY; Chuang KH; Sheu MT
Drug Deliv; 2018 Nov; 25(1):1066-1079. PubMed ID: 29718725
[TBL] [Abstract][Full Text] [Related]
7. Active Tumoral/Tumor Environmental Dual-Targeting by Non-Covalently Arming with Trispecific Antibodies or Dual-Bispecific Antibodies on Docetaxel-Loaded mPEGylated Nanocarriers to Enhance Chemotherapeutic Efficacy and Minimize Systemic Toxicity.
Cheng WJ; Lin SY; Chen M; Chen LC; Ho HO; Chuang KH; Sheu MT
Int J Nanomedicine; 2021; 16():4017-4030. PubMed ID: 34140769
[TBL] [Abstract][Full Text] [Related]
8. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.
Ho KW; Chen IU; Cheng YA; Liao TY; Liu ES; Chen HJ; Lu YC; Su YC; Roffler SR; Huang BC; Liu HJ; Huang MY; Chen CY; Cheng TL
J Nanobiotechnology; 2021 Jan; 19(1):16. PubMed ID: 33422061
[TBL] [Abstract][Full Text] [Related]
9. Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors.
Wu SC; Chen YJ; Wang HC; Chou MY; Chang TY; Yuan SS; Chen CY; Hou MF; Hsu JT; Wang YM
Theranostics; 2016; 6(1):118-30. PubMed ID: 26722378
[TBL] [Abstract][Full Text] [Related]
10. Overcoming Instability of Antibody-Nanomaterial Conjugates: Next Generation Targeted Nanomedicines Using Bispecific Antibodies.
Howard CB; Fletcher N; Houston ZH; Fuchs AV; Boase NR; Simpson JD; Raftery LJ; Ruder T; Jones ML; de Bakker CJ; Mahler SM; Thurecht KJ
Adv Healthc Mater; 2016 Aug; 5(16):2055-68. PubMed ID: 27283923
[TBL] [Abstract][Full Text] [Related]
11. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
13. Targeted siRNA delivery by anti-HER2 antibody-modified nanoparticles of mPEG-chitosan diblock copolymer.
Wang Y; Liu P; Du J; Sun Y; Li F; Duan Y
J Biomater Sci Polym Ed; 2013; 24(10):1219-32. PubMed ID: 23713424
[TBL] [Abstract][Full Text] [Related]
14. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
15. A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery.
Liu P; Yu H; Sun Y; Zhu M; Duan Y
Biomaterials; 2012 Jun; 33(17):4403-12. PubMed ID: 22436800
[TBL] [Abstract][Full Text] [Related]
16. Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma.
Liu XJ; Li L; Liu XJ; Li Y; Zhao CY; Wang RQ; Zhen YS
Int J Nanomedicine; 2017; 12():5255-5269. PubMed ID: 28769562
[TBL] [Abstract][Full Text] [Related]
17. Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation.
Xin H; Chen L; Gu J; Ren X; Wei Z; Luo J; Chen Y; Jiang X; Sha X; Fang X
Int J Pharm; 2010 Dec; 402(1-2):238-47. PubMed ID: 20934500
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel biocompatible poly(ethylene glycol)-block-poly(γ-cholesterol-L-glutamate) as hydrophobic drug carrier.
Ma Q; Li B; Yu Y; Zhang Y; Wu Y; Ren W; Zheng Y; He J; Xie Y; Song X; He G
Int J Pharm; 2013 Mar; 445(1-2):88-92. PubMed ID: 23376505
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor-2 antibodies enhance the specificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes.
Li Q; Tang Q; Zhang P; Wang Z; Zhao T; Zhou J; Li H; Ding Q; Li W; Hu F; Du Y; Yuan H; Chen S; Gao J; Zhan J; You J
Biomaterials; 2015 Jul; 57():1-11. PubMed ID: 25956192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
